Latest Insider Transactions at Nuvalent, Inc. (NUVL)
This section provides a real-time view of insider transactions for Nuvalent, Inc. (NUVL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuvalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuvalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,483
-1.34%
|
$196,157
$79.38 P/Share
|
|
Jan 06
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+23.09%
|
-
|
|
Jan 06
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.63%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Darlene Noci Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+26.48%
|
-
|
|
Jan 06
2025
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.05%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Christopher Durant Turner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+21.98%
|
-
|
|
Jan 06
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,964
-1.93%
|
$234,156
$79.38 P/Share
|
|
Jan 06
2025
|
Deborah Ann Miller Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+26.48%
|
-
|
|
Jan 06
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
17,301
-2.21%
|
$1,366,779
$79.38 P/Share
|
|
Jan 06
2025
|
James Richard Porter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+17.44%
|
-
|
|
Jan 06
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.07%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+22.19%
|
-
|
|
Dec 23
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.45%
|
$166,000
$83.9 P/Share
|
|
Dec 19
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+9.48%
|
$0
$0.65 P/Share
|
|
Dec 17
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,700
+13.54%
|
$41,100
$3.99 P/Share
|
|
Dec 16
2024
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,414
+11.22%
|
$0
$0.76 P/Share
|
|
Dec 16
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-6.46%
|
$2,322,000
$86.71 P/Share
|
|
Dec 16
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
|
Dec 11
2024
|
Andrew A. F. Hack |
SELL
Open market or private sale
|
Indirect |
1,250,000
-46.34%
|
$110,000,000
$88.0 P/Share
|
|
Dec 05
2024
|
Grant C. Bogle |
BUY
Grant, award, or other acquisition
|
Direct |
3,200
+50.0%
|
-
|
|
Nov 29
2024
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-12.04%
|
$950,000
$95.97 P/Share
|
|
Nov 29
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.76%
|
$270,000
$27.85 P/Share
|
|
Nov 25
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.3%
|
$192,000
$96.6 P/Share
|
|
Nov 15
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-3.28%
|
$2,376,000
$88.47 P/Share
|
|
Nov 15
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
|
Nov 01
2024
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.53%
|
$440,000
$88.94 P/Share
|
|
Nov 01
2024
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.55%
|
$70,000
$14.4 P/Share
|
|
Oct 31
2024
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-6.18%
|
$890,000
$89.67 P/Share
|
|
Oct 31
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.76%
|
$270,000
$27.85 P/Share
|
|
Oct 28
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.3%
|
$184,000
$92.23 P/Share
|
|
Oct 22
2024
|
James E Flynn Director |
SELL
Open market or private sale
|
Indirect |
2,000,000
-10.34%
|
$194,000,000
$97.75 P/Share
|
|
Oct 15
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-6.3%
|
$2,754,000
$102.64 P/Share
|
|
Oct 15
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
|
Oct 01
2024
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.3%
|
$510,000
$102.37 P/Share
|
|
Oct 01
2024
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.55%
|
$90,000
$18.93 P/Share
|
|
Sep 30
2024
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-6.26%
|
$1,000,000
$100.5 P/Share
|
|
Sep 30
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.76%
|
$270,000
$27.85 P/Share
|
|
Sep 23
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.13%
|
$208,000
$104.43 P/Share
|
|
Sep 16
2024
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,000
-3.0%
|
$776,000
$97.46 P/Share
|
|
Sep 16
2024
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+16.23%
|
$144,000
$18.93 P/Share
|
|
Sep 16
2024
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
32,795
-6.47%
|
$3,213,910
$98.26 P/Share
|
|
Sep 09
2024
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.1%
|
$261,000
$87.88 P/Share
|
|
Sep 09
2024
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+7.63%
|
$18,000
$6.89 P/Share
|
|
Sep 03
2024
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.53%
|
$420,000
$84.72 P/Share
|
|
Sep 03
2024
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.55%
|
$90,000
$18.93 P/Share
|
|
Aug 30
2024
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.24%
|
$840,000
$84.79 P/Share
|
|
Aug 30
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.76%
|
$270,000
$27.85 P/Share
|
|
Aug 26
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.29%
|
$168,000
$84.71 P/Share
|
|
Aug 23
2024
|
Emily Conley |
SELL
Open market or private sale
|
Direct |
3,334
-57.08%
|
$283,390
$85.02 P/Share
|
|
Aug 23
2024
|
Emily Conley |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+36.34%
|
$43,342
$13.79 P/Share
|